Meridian Bioscience, a provider of diagnostic testing solutions and life science raw materials, announced that it will increase production capacity of the company's SARS-CoV-2 molecular diagnostic test on its Revogene platform after receiving a $5.5M award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative and an additional grant from JobsOhio, according to a company press release.
The funding will help Meridian expand production of Revogene test kits in the Quebec City facility and build a new semi-automated, state-of-the-art, two-line production facility near the company’s corporate headquarters in the Village of Newtown, near Cincinnati, OH. The expansion will be completed in phases over the coming months and is expected to yield a maximum capacity of 800,000 Revogene tests per month by the end of calendar year 2021.
